Industry comments
On March 22, the State Food and Drug Administration issued a public solicitation of opinions on the quality management norms for drug operation - appendix for the quality management of drug retail distribution (Draft for comments). The draft points out that drug retail enterprises should take effective quality control measures in the process of drug distribution, meet the requirements of drug information traceability, and realize the controllable and traceable quality of the whole process of drug distribution. Drug retail enterprises shall allocate full-time or part-time personnel to be responsible for the quality management of drug distribution. Relevant personnel shall be familiar with the laws and regulations related to drug circulation management, and have the ability to make independent and correct judgment and ensure implementation in the quality management of drug distribution. The drug operation quality standard will have a direct impact on major retail pharmacies. At the same time, the drug retail distribution quality management will put forward new requirements for the pharmaceutical logistics industry.
In March 23rd, the national health and Health Committee issued a notice on adjusting the indications of anti New Coronavirus drugs PF-07321332/ Ritonavir Tablets (Paxlovid). The drug name was adjusted to "namatvir tablets / ritonavir tablets combined packaging", and the indication was adjusted to "adults with light and common types within 5 days of onset and accompanied by high-risk factors for severe disease." The usage and dosage is "300mg nimatovir tablets and 100mg ritonavir tablets are taken at the same time, once every 12 hours for 5 consecutive days." In addition, the notice also suggests that it is forbidden for patients who are allergic to the active ingredients or any excipients in this product. Some cdmo companies that have obtained covid-19 small molecule drug orders will usher in performance increment.
On March 25, the national medical insurance bureau released the information, and the coverage of direct inter provincial settlement of outpatient expenses was further expanded. 826 designated medical institutions in 63 areas of the country have launched 5 pilot outpatient direct settlement experiments, including hypertension, diabetes, cancer out-patient chemoradiotherapy, uremic dialysis, anti rejection treatment after organ transplantation, and so on. The launch of the pilot of inter provincial direct settlement of outpatient expenses will provide patients with more convenience and further increase their choice space. At the same time, inter provincial direct settlement promotes the release of downstream demand, and the prosperity of medical informatization industry is improved. In addition, the liquidity of dialysis business increases, and the demand also increases.
On March 25, the National Health Commission, the national development and Reform Commission, the Department of civil affairs and other nine departments jointly issued the notice on carrying out the action to improve the ability of community medical care integration, which defined the work objectives, work contents and relevant requirements of the action to improve the service ability of community medical care integration. The goal of the work is to make effective use of existing resources such as grass-roots medical and health care and elderly care services, improve the ability of home-based community medical and elderly care services, and effectively meet the health and elderly care service needs of the elderly within the jurisdiction. The purpose of this action is to meet the health and elderly care service needs of the elderly and improve their living standards. At the same time, "digital pension" continues to rise, injecting new momentum into pension services. In addition, the combination of traditional Chinese medicine and nursing medicine is gradually becoming an important part of the development trend of traditional Chinese medicine.
Investment advice
It is suggested to pay attention to the pharmaceutical circulation, covid-19 specific drug industry chain, medical informatization, digital health and traditional Chinese medicine industry.
Risk tips
The risk of expanding the scope of centralized procurement, the risk of price reduction exceeding expectations, the risk of product supply falling short of expectations after winning the bid, the risk of epidemic uncertainty, and other policy and market risks.
